Ivermectin treatment for gynecologic cancers: hope versus hype
An editorial accompanying the gynaecological review: repurposing is legitimate and early trials deserve support, but no major oncology organisation endorses ivermectin for cancer and patients should not forgo proven treatment for it.
Overview
The editorial describes drug repurposing as a sound strategy whose usual failure mode is that agents active in cell culture or mice do not deliver clinical benefit in randomised trials (Straughn editorial 2025). It states that no major oncology organisations, including ASCO, SGO or NCCN, currently endorse ivermectin for cancer treatment, that the clinical evidence is not sufficient to support its use, and that ivermectin used outside approved dosing carries real risks of toxicity and drug interactions (Straughn editorial 2025). It welcomes the early-phase trials now under way and asks the oncology community to resist leaping ahead of the science (Straughn editorial 2025).
- No major oncology organisation endorses ivermectin for cancer treatment.
- Early-phase trials are under way and deserve support and scrutiny.
A measured position a patient can take to their oncologist: the drug is being tested properly, and until those tests report, it is not a treatment.
- Editorial opinion, not a systematic review.
Similar pages
not linked directly; found by shared links- TrialAtavistic chemotherapy: combinations of antibacterial, antifungal and antiprotozoal drugs in advanced cancer (Arguello clinic, status unknown)
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperCancer therapy using antiparasitic medications guided by acupuncture meridian assessment: a case series of six patients
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperThe multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Systematic drug repurposing, Ivermectin.
- Key paperIvermectin-benzimidazole prescribing following celebrity endorsement
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperReal-world clinical outcomes of ivermectin and mebendazole in cancer patients: results from a prospective observational cohort (with 2026 expression of concern)
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperRETRACTED: Fenbendazole as an anticancer agent? A case series of self-administration in three patients
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Misinformation and unproven therapies.
- Key paperIvermectin in cancer treatment: should healthcare providers caution or explore its therapeutic potential?
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin, Misinformation and unproven therapies.
- Key paperMetastatic melanoma with initial ctDNA decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression?
Shares Fenbendazole, ivermectin and other internet 'repurposed cures', Ivermectin.